Impel Pharmaceuticals Inc.
IMPL · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $10 | $30 | $33 | $89 |
| - Cash | $0 | $15 | $35 | $61 |
| + Debt | $115 | $52 | $53 | $51 |
| Enterprise Value | $125 | $67 | $51 | $80 |
| Revenue | $5 | $7 | $4 | $5 |
| % Growth | -23.7% | 50.6% | -12.7% | – |
| Gross Profit | $3 | $3 | $2 | $3 |
| % Margin | 55.6% | 51.1% | 47.7% | 55.7% |
| EBITDA | -$17 | -$16 | -$24 | -$6 |
| % Margin | -335.3% | -244.6% | -558.9% | -114% |
| Net Income | -$14 | -$7 | -$39 | -$36 |
| % Margin | -275% | -111.7% | -883.6% | -725.1% |
| EPS Diluted | -0.58 | -0.31 | -1.63 | -1.53 |
| % Growth | -87.1% | 81% | -6.5% | – |
| Operating Cash Flow | -$17 | -$20 | -$24 | -$18 |
| Capital Expenditures | -$1 | $0 | -$1 | -$1 |
| Free Cash Flow | -$17 | -$20 | -$25 | -$19 |